FMA
ARLZ

FNY Managed Accounts’s Aralez Pharmaceuticals Inc. ARLZ Stock Holding History

FNY Managed Accounts’s Portfolio ARLZ Stock Details ARLZ Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2017
Q2 		– Sell
-77,119
Closed -$165K – 825
2017
Q1 		$165K Buy
77,119
+3,136
+4% +$11.8K 0.51% 30
2016
Q4 		$326K Buy
73,983
+14,983
+25% +$71.1K 2.19% 8
2016
Q3 		$286K Buy
59,000
+7,000
+13% +$31.9K 0.24% 80
2016
Q2 		$172K Buy
52,000
+22,000
+73% +$83K 0.16% 78
2016
Q1 		$107K Buy
+30,000
New +$155K 0.19% 93

Other funds holding ARLZ

PCM
PAR Capital Management Boston, Massachusetts $3.45B AUM 28.5% 1-Year Est. Return
BC
Broadfin Capital New York $747M AUM 100.56% 1-Year Est. Return
DM
Deerfield Management New York $8.48B AUM 99.04% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Deutsche Bank
Deutsche Bank Frankfurt Am Main Ge, Germany $303B AUM 30.15% 1-Year Est. Return
GCP
GSA Capital Partners London, United Kingdom $1.61B AUM 28.28% 1-Year Est. Return
JAM
JW Asset Management Miami Beach, Florida $244M AUM 71.51% 1-Year Est. Return
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
CIM
Contrarius Investment Management St. Helier, Jersey $1.76B AUM 35.87% 1-Year Est. Return

FNY Managed Accounts's ARLZ Position: Q2 2017 in Review

FNY Managed Accounts sold out of Aralez Pharmaceuticals Inc. (ARLZ) in Q2 2017, closing a stake of 77,119 shares — an estimated $165K sold.

FNY Managed Accounts first reported a position in ARLZ in Q1 2016 and held it in 5 quarters. The position peaked at $326K in Q4 2016. 72 funds tracked by Wall St. Rank hold ARLZ as of Q2 2017.

  • FNY Managed Accounts reported no remaining Aralez Pharmaceuticals Inc. position as of Q2 2017 after selling out during the quarter.
  • FNY Managed Accounts sold 77,119 Aralez Pharmaceuticals Inc. shares in Q2 2017, an estimated $165K.
  • FNY Managed Accounts first reported a position in Aralez Pharmaceuticals Inc. in Q1 2016 and held it in 5 quarters.
  • FNY Managed Accounts's Aralez Pharmaceuticals Inc. position peaked at $326K in Q4 2016.
  • 72 funds tracked by Wall St. Rank held Aralez Pharmaceuticals Inc. as of Q2 2017.

Based on FNY Managed Accounts's 13F filing for Q2 2017, filed 10 Aug 2017.